Third Cycle of Medicare Price Negotiations
The U.S. Centers for Medicare & Medicaid Services (CMS) announced Tuesday a new roster of branded drugs selected for the third cycle of the Medicare Drug Price Negotiation Program. This landmark expansion includes products from pharmaceutical giants Eli Lilly, Pfizer, and AbbVie, marking a significant milestone as the program incorporates its first products reimbursed under Medicare Part B.
The current negotiation round targets 15 prescription medications, with discussions scheduled to conclude this Saturday. Among the selected drugs are AbbVie’s Linzess, used to treat irritable bowel syndrome, and Vraylar, an antipsychotic medication. These price reductions, while not yet publicly disclosed, are slated to take effect in 2027.
Historical Context of Medicare Negotiations
Last year, the Biden administration successfully negotiated price cuts on 10 top-selling prescription drugs, anticipating savings of $6 billion in 2026 alone. AbbVie’s leukemia treatment Imbruvica received the most modest discount in those negotiations, with a 38% reduction—the lowest percentage cut among the selected medications. Other drugs in the 2024 cycle saw discounts reaching as high as 79%, setting a precedent for aggressive pricing negotiations.
Trump Administration’s Aggressive Pricing Strategy
According to AbbVie’s Friday statement, the Trump administration is advocating for substantially steeper price cuts compared to previous negotiation cycles. President Donald Trump has made lowering prescription drug costs a central priority of his healthcare agenda this year, intensifying pressure on pharmaceutical manufacturers.
Industry analysts are closely monitoring whether the Trump administration will secure deeper discounts than its predecessor achieved. This shift in negotiation intensity reflects the current administration’s commitment to reducing healthcare costs for Medicare beneficiaries while potentially impacting pharmaceutical company revenues and long-term strategic planning.
Despite the anticipated steeper discounts, AbbVie has assured investors that these cuts will not materially affect the company’s long-term financial guidance, demonstrating confidence in its diversified product portfolio.
AbbVie’s Financial Performance and Outlook
Strong Immunology Portfolio Drives Growth
AbbVie exceeded third-quarter expectations on Friday, reporting quarterly sales of $15.78 billion against analyst estimates of $15.59 billion, according to LSEG data. The North Chicago-based pharmaceutical company raised its 2025 adjusted annual profit forecast to between $10.61 and $10.65 per share, up from the previous range of $10.38 to $10.58.
This optimistic outlook stems primarily from robust performance of newer immunology medications Skyrizi and Rinvoq. Chief Financial Officer Scott Reents announced that the company now expects 2025 global Skyrizi sales to reach $17.3 billion—$200 million higher than previously forecasted. During the third quarter, Skyrizi generated $4.71 billion in sales, surpassing estimates of $4.44 billion, while Rinvoq brought in $2.18 billion, exceeding the $2.12 billion projection.
Humira’s Historic Decline
The company’s once-dominant arthritis treatment Humira continued its downward trajectory, recording third-quarter sales of $993 million—falling short of the $1.15 billion estimate. This marks the first time Humira’s quarterly revenue has dropped below $1 billion since biosimilar competition launched in the United States in 2023. AbbVie has strategically positioned Skyrizi and Rinvoq to compensate for this anticipated erosion.
Aesthetic Products Face Headwinds
AbbVie shares dropped more than 4% following news that aesthetic product sales, including the popular anti-wrinkle treatment Botox, declined 3.7% year-over-year. BMO Capital Markets analyst Evan Seigerman noted that “another weaker quarter for the aesthetics business could raise some eyebrows,” citing continued challenges across multiple products including Botox and dermal fillers.
Jeffrey Stewart, AbbVie’s Chief Commercial Officer, attributed the weakness to economic concerns and inflation pressures affecting consumer discretionary spending, pulling category growth below the company’s global assumptions.
Impact on Pharmaceutical Industry
The intensified Medicare price negotiations are reshaping pharmaceutical industry dynamics. As third-quarter earnings season progresses, analysts are scrutinizing how companies are preparing for potentially more aggressive discount requirements under the Trump administration.
Bernstein analyst Courtney Breen observed that while AbbVie’s Skyrizi and Rinvoq “managed to pull it out of the bag,” the performance gap between actual results and consensus estimates is narrowing compared to previous quarters, suggesting increasing market maturation and competitive pressures.
The company reported quarterly earnings per share of $1.86, beating analyst expectations of $1.77, demonstrating operational efficiency despite market headwinds. AbbVie projects fourth-quarter 2025 net sales of $16.3 billion, maintaining confidence in its growth trajectory.
Future Implications
The Medicare Drug Price Negotiation Program continues to evolve as a critical mechanism for controlling healthcare costs while maintaining pharmaceutical innovation incentives. The 2027 implementation of the current negotiation cycle’s price cuts will provide important data on the program’s long-term sustainability and impact on drug development investment.
Industry observers anticipate that pharmaceutical companies will increasingly focus on pipeline diversification and operational efficiency to offset revenue pressures from negotiated price reductions, while policymakers balance affordability objectives with innovation preservation.
